UNSPSC 51241113: Physostigmine

This classification denotes an acetylcholinesterase inhibitor with the molecular formula 2C15H21N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G63V2J2N71, chemically known as pyrrolo(2,3-b)indole, 1,2,3,3a,8,8a-hexahydro-5-hydroxy-1,3a,8-trimethyl-, methylcarbamate (ester), (3as-cis)-, sulfate (2:1) but generally known as physostigmine sulfate, which bears US NIH Compound Identifier 6150.

European Medicines Agency schedules Physostigmine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14866MIG. As of Q4 2014, PHYSOSTIGMINE remains the US FDA Preferred Term for this commodity.

UNSPSC 51241113 Physostigmine is a Commodity code covering individual pharmaceutical products supplied through state and local procurement channels. State and local governments procure physostigmine and related pharmaceuticals primarily through cooperative purchasing alliances and direct contracts with pharmaceutical manufacturers and wholesalers. The work entails manufacturing and distributing FDA-compliant generic pharmaceuticals to state facilities, schools, health departments, and other public entities, with vendors required to meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with authorized wholesalers, and provide detailed product specifications including National Drug Codes (NDC), SKUs, and pricing in multiple formats (flat price, net price, or WAC-minus structures).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026 for a two-year term. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.